Q1 Earnings Estimate for LXRX Issued By HC Wainwright

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for Lexicon Pharmaceuticals in a research report issued to clients and investors on Thursday, March 5th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will earn ($0.06) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.20) EPS, FY2029 earnings at ($0.20) EPS and FY2030 earnings at ($0.12) EPS.

Other equities analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Lexicon Pharmaceuticals has a consensus rating of “Hold” and an average price target of $3.95.

Lexicon Pharmaceuticals Trading Down 1.8%

Shares of LXRX opened at $1.68 on Monday. The stock has a market capitalization of $711.78 million, a PE ratio of -12.00 and a beta of 0.94. The company’s fifty day moving average is $1.37 and its 200 day moving average is $1.34. The company has a debt-to-equity ratio of 0.46, a quick ratio of 4.87 and a current ratio of 4.88. Lexicon Pharmaceuticals has a fifty-two week low of $0.32 and a fifty-two week high of $1.83.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, March 5th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 41.94% and a negative net margin of 101.08%.The business had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $3.14 million.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in LXRX. Virtu Financial LLC purchased a new position in Lexicon Pharmaceuticals in the 4th quarter worth about $42,000. Invesco Ltd. boosted its position in Lexicon Pharmaceuticals by 14.1% in the 4th quarter. Invesco Ltd. now owns 594,883 shares of the biopharmaceutical company’s stock valued at $684,000 after buying an additional 73,480 shares during the period. Millennium Management LLC grew its stake in Lexicon Pharmaceuticals by 25.9% in the 4th quarter. Millennium Management LLC now owns 4,821,733 shares of the biopharmaceutical company’s stock worth $5,545,000 after acquiring an additional 991,073 shares in the last quarter. Ishara Investments LP purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth approximately $1,012,000. Finally, ExodusPoint Capital Management LP purchased a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth approximately $309,000. 74.70% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Lexicon Pharmaceuticals

In other news, Director Invus Global Management, Llc bought 1,538,462 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, February 2nd. The shares were acquired at an average price of $1.30 per share, with a total value of $2,000,000.60. Following the completion of the purchase, the director owned 1,538,462 shares in the company, valued at $2,000,000.60. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Raymond Debbane bought 100,000 shares of the stock in a transaction dated Monday, February 23rd. The stock was purchased at an average price of $1.47 per share, with a total value of $147,000.00. Following the acquisition, the director directly owned 1,904,186 shares in the company, valued at approximately $2,799,153.42. The trade was a 5.54% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 1,790,462 shares of company stock worth $2,369,981 in the last 90 days. 13.90% of the stock is currently owned by insiders.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.